Journal of Clinical Oncology

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR

PURPOSE EA1181 (ClinicalTrials.gov identifier: NCT04266249 ) is a single-arm trial evaluating neoadjuvant taxane,...

Practice Change Following Small Trials in Rare Cancers With Rare Biomarkers

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...

Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study

PURPOSE Laser interstitial thermal therapy is a surgical tool used to ablate brain tumors, radiation necrosis, and epileptic foci. Data from the LAANTERN pro...

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...

Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma

PURPOSE Chemoimmunotherapy has been the standard approach for untreated indolent B-cell lymphoma. We hypothesized that initial use of the CD3/CD20 bispecific mosunetuzumab followed...

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Advanced Melanoma

The COMBI-I trial (ClinicalTrials.gov identifier: NCT02967692 ) evaluating spartalizumab plus dabrafenib and trametinib (sparta-DabTram, n = 267) versus placebo...

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas

PURPOSE Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It i...

Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression

PURPOSE Systemic treatment options for advanced salivary gland carcinoma (SGC) are limited, and prospective data for human epidermal growth factor receptor 2 (HER2)–directed therap...

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial

Daromun (L19IL2/L19TNF) was investigated as a neoadjuvant, intralesional therapy for patients with fully resectable stage III melanoma in the phase III PIVOTAL trial (ClinicalTrials.gov identifier:...

Forty

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia

Relapsed or refractory (RR) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) presents increasing therapeutic complexity in the era of targeted agents. Frontline use of covalent Bruton...

Should Artificial Intelligence Direct Systemic Therapy Decisions in Pancreatic Cancer?

Therapeutic Strategy Concerns for <i>BRAF</i> V600E–Mutated Differentiated Thyroid Cancer

Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2

PURPOSE Dexrazoxane has been associated with preservation of left ventricular (LV) systolic function in relatively small studies of long-term childhood cancer survivors. What remai...

Reply to: Therapeutic Strategy Concerns for <i>BRAF</i> V600E–Mutated Differentiated Thyroid Cancer

Modernizing Drug Development for Exceptional Therapies in High‑Unmet Need Diseases: A Call for Pragmatism and Patient Centricity

Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...

Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration

Unexpected Lack of Efficacy of Liposomal-Encapsulated Daunorubicin/Cytarabine in Pediatric <i>FLT3</i> Wild-Type Newly Diagnosed AML

NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002

Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development

Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example

Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”